Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
Some of our patients often tell us they need to experience some undesirable truth first-hand to believe it. Implied is the ...
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...
St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...
Ketamine is an old anesthesia drug with psychedelic qualities, and it has been getting a lot of attention for its ability to ...
We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...
Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...
A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results